MiniMed launches Nasdaq Global Select IPO as second-largest Medtech offering
MiniMed Group began trading on the Nasdaq Global Select Market under symbol MMED after an oversubscribed IPO that ranked as the second-largest offering in medical technology history. Carved out from Medtronic, the standalone diabetes-care company will leverage its integrated insulin delivery systems to accelerate growth and operational agility.
1. IPO Launch and Trading
On March 6, MiniMed Group, Inc. began trading on the Nasdaq Global Select Market under ticker MMED, completing an oversubscribed initial public offering that became the second-largest IPO in medical technology history.
2. Strategic Independence and Medtronic Support
The IPO establishes MiniMed as a standalone diabetes-care company spun out from Medtronic, enabling focused investment in its integrated insulin delivery systems and connected devices while Medtronic reallocates capital toward core medical technology segments.
3. Leadership and Future Outlook
CEO Que Dallara rang the Opening Bell to mark the debut, underscoring MiniMed’s 40-year legacy across 80 countries and its roadmap to innovate full-stack insulin delivery solutions that drive market expansion and operational agility.